A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

Schroder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Schroder, 2012, Prostate-cancer mortality at 11 years of follow-up, N Engl J Med, 366, 981, 10.1056/NEJMoa1113135 Schroder, 2014, Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 384, 2027, 10.1016/S0140-6736(14)60525-0 Martin, 2018, Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial, JAMA, 319, 883, 10.1001/jama.2018.0154 2017 De Koning, 2002, Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial, Int J Cancer, 98, 268, 10.1002/ijc.10188 De Koning, 2003, Determining the cause of death in randomized screening trial(s) for prostate cancer, BJU Int, 92, 71, 10.1111/j.1465-5101.2003.04402.x Makinen, 2008, Assessment of causes of death in a prostate cancer screening trial, Int J Cancer, 122, 413, 10.1002/ijc.23126 Aalen, 1978, Nonparametric inference for a family of counting processes, Ann Stat, 6, 701, 10.1214/aos/1176344247 DeMets, 1994, Interim analysis: the alpha spending function approach, Stat Med, 13, 1341, 10.1002/sim.4780131308 Kalbfleisch, 1980 Cuzick, 1997, Adjusting for non-compliance and contamination in randomized clinical trials, Stat Med, 16, 1017, 10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V Fenton, 2018, Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force, JAMA, 319, 1914, 10.1001/jama.2018.3712 Rider, 2013, Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study, Eur Urol, 63, 88, 10.1016/j.eururo.2012.08.001 Gotzsche, 2011, Screening for breast cancer with mammography, Cochrane Database Syst Rev, 1, CD001877 Draisma, 2003, Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer, J Natl Cancer Inst, 95, 868, 10.1093/jnci/95.12.868 Heijnsdijk, 2012, Quality-of-life effects of prostate-specific antigen screening, N Engl J Med, 367, 595, 10.1056/NEJMoa1201637 Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993 Roobol, 2007, Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam, J Natl Cancer Inst, 99, 1296, 10.1093/jnci/djm101 Schroder, 2012, Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC), Eur Urol, 62, 745, 10.1016/j.eururo.2012.05.068 Lundgren, 2018, Long-term outcome of a single intervention population based prostate cancer screening study, J Urol, 200, 82, 10.1016/j.juro.2018.01.080 Andriole, 2009, Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 360, 1310, 10.1056/NEJMoa0810696 Andriole, 2012, Prostate cancer screening in the randomized Prostate, Lung Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up, J Natl Cancer Inst, 104, 125, 10.1093/jnci/djr500 Tsodikov, 2017, Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials, Ann Intern Med, 167, 449, 10.7326/M16-2586 Kilpelainen, 2017, Estimate of opportunistic prostate specific antigen testing in the Finnish Randomized Study of Screening for Prostate Cancer, J Urol, 198, 50, 10.1016/j.juro.2017.01.048 Hugosson, 2018, Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality, Scand J Urol, 52, 27, 10.1080/21681805.2017.1411392 De Koning, 2018, The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials, Cancer, 124, 1197, 10.1002/cncr.31178